"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...
– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced the first patient was dosed with lenzilumab in the Precision Approach to Chronic Myelomonocytic ...
The prognostic impact of monocytosis in patients with myelodysplastic syndromes (MDS) is not well-studied and not been clearly defined. Patients with MDS and monocytosis had a shorter overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback